TAK NYSE
Takeda Pharmaceutical Company Limited
1W: +4.2%
1M: +10.7%
3M: +16.6%
YTD: +30.8%
1Y: +45.3%
3Y: +52.9%
5Y: +73.7%
$20.27
-0.16 (-0.78%)
After Hours: $20.30 (+0.04, +0.17%)
Weekly Expected Move ±3.0%
$19
$20
$20
$21
$21
Credit Risk of going bust: lower than 78% of companies Debt: 32.5% of company value Bonds: $208.5M held by 194 funds, 85 bp over Treasuries → details ▾
If the stock fell to about $0.49 (down 98%), Takeda Pharmaceutical Company Limited would be worth roughly what it owes.
Total debt $31.37B against a stock market value of $65.02B.
Distance to default 9.16 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $17.34B (short-term plus half of long-term), stock volatility 21.6%; Altman Z'' 1.53. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Total debt $31.37B against a stock market value of $65.02B.
Distance to default 9.16 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $17.34B (short-term plus half of long-term), stock volatility 21.6%; Altman Z'' 1.53. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
#1
of 26
Drug Manufacturers - Specialty & Generic
Technical Signal Map
10 Bullish
0 Neutral
1 Bearish
TAK
$63B
Takeda Pharmaceutical Company Limited
BULLISH
+91
SDZNY
$42B
Sandoz Group AG
BULLISH
+91
RDY
$11B
Dr. Reddy's Laboratories Limited
BULLISH
+84
ZTS
$33B
Zoetis Inc.
BULLISH
+78
VTRS
$21B
Viatris Inc.
BULLISH
+75
HLN
$45B
Haleon plc
BULLISH
+53
TEVA
$46B
Teva Pharmaceutical Industries Limited
BULLISH
+49
SGIOY
$16B
Shionogi & Co., Ltd.
BULLISH
+34
IPSEY
$58B
Ipsen S.A.
LEAN BULL
+18
MKGAF
$70B
Merck KGaA
LEAN BULL
+16
ELAN
$11B
Elanco Animal Health Incorporated
BEARISH
-65
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| TAK Takeda Pharmaceutical Company Limited | $63B | 56.1 | 2.5 | 2.9 | 9.3 | 4.0 | 6 | BULLISH | 44.8 |
| SDZNY Sandoz Group AG | $42B | 66.5 | 7.2 | 10.1 | 1.9 | 29.1 | 6 | BULLISH | 59.1 |
| RDY Dr. Reddy's Laboratories Limited | $11B | 39.0 | 7.5 | 6.0 | 10.7 | -3.1 | 4 | BULLISH | -5.7 |
| ZTS Zoetis Inc. | $33B | 12.9 | 64.4 | 26.3 | 28.0 | 1.4 | 6 | BULLISH | -46.2 |
| VTRS Viatris Inc. | $21B | -52.2 | -2.8 | -0.3 | -3.2 | 4.4 | 7 | BULLISH | 83.0 |
| HLN Haleon plc | $45B | 20.7 | 10.1 | 8.4 | 13.6 | 1.3 | 8 | BULLISH | 8.9 |
| TEVA Teva Pharmaceutical Industries Limited | $46B | 64.2 | 9.7 | 9.3 | -13.9 | 4.1 | 7 | BULLISH | 113.2 |
| SGIOY Shionogi & Co., Ltd. | $16B | 9.8 | 13.6 | 9.9 | 50.6 | 10.3 | 5 | BULLISH | 20.6 |
| IPSEY Ipsen S.A. | $58B | 24.6 | 11.5 | 16.3 | 18.2 | 8.0 | 6 | LEAN BULL | 22.7 |
| MKGAF Merck KGaA | $70B | 26.5 | 8.1 | 8.1 | 9.0 | -0.4 | 7 | LEAN BULL | 19.4 |
| ELAN Elanco Animal Health Incorporated | $11B | -55.3 | -3.0 | 3.7 | 3.9 | 12.0 | 5 | BEARISH | 2.7 |
| TAK Takeda Pharmaceutical Company Limited | $63B | 56.1 | 2.5 | 2.9 | 9.3 | 4.0 | 6 | BULLISH | 44.8 |
| LZAGY Lonza Group AG | $54B | -412.9 | 13.5 | 10.5 | 17.5 | -9.7 | 8 | BULLISH | 4.3 |
| EW Edwards Lifesciences Corporation | $51B | 52.1 | 9.5 | 17.9 | 13.9 | 14.6 | 6 | BULLISH | 19.3 |
| CI Cigna Corporation | $81B | 12.3 | 15.5 | 11.8 | 2.3 | 7.7 | 8 | BULLISH | -0.6 |
| NTRA Natera, Inc. | $58B | -303.0 | -12.5 | -23.6 | -8.9 | 37.8 | 6 | BULLISH | 113.4 |
| WAT Waters Corporation | $45B | 116.7 | 1.9 | 1.5 | -8.3 | 52.5 | 5 | BULLISH | 30.3 |
| CHGCF Chugai Pharmaceutical Co., Ltd. | $74B | 23.3 | 23.7 | 45.1 | 34.1 | 12.6 | 6 | BULLISH | -0.7 |
| CAH Cardinal Health, Inc. | $58B | 34.0 | -60.5 | 92.8 | 0.6 | 14.2 | 8 | BULLISH | 53.7 |
| BDX Becton, Dickinson and Company | $54B | 58.9 | 3.8 | 4.1 | 7.6 | -2.6 | 6 | BULLISH | 5.5 |
| A Agilent Technologies, Inc. | $49B | 35.1 | 21.0 | 14.9 | 19.3 | 8.6 | 7 | BULLISH | 19.9 |
| IQV IQVIA Holdings Inc. | $46B | 32.9 | 21.7 | 33.3 | 7.9 | 8.8 | 9 | BULLISH | 23.1 |
| SEMHF Siemens Healthineers AG | $53B | 21.1 | 12.1 | 8.4 | 11.6 | 10.0 | 9 | BULLISH | -17.9 |
| MRNA Moderna, Inc. | $80B | -25.8 | -39.0 | -90.1 | -539.3 | -27.2 | 2 | BULLISH | 724.0 |
| HOCPY HOYA Corporation | $56B | 33.4 | 27.3 | 46.1 | 25.7 | 14.2 | 6 | BULLISH | 12.2 |
| BSX Boston Scientific Corporation | $66B | 18.1 | 15.5 | 11.6 | 16.7 | 13.5 | 8 | BULLISH | -55.4 |
| HUM Humana Inc. | $51B | 38.9 | 6.8 | 17.2 | 1.7 | 18.3 | 4 | BULLISH | 42.7 |
| UCBJY UCB S.A. | $58B | 23.3 | 20.7 | 16.4 | 26.0 | 25.3 | 6 | LEAN BULL | 5.8 |
| COR Cencora, Inc. | $63B | 24.2 | 104.3 | 26.5 | 0.9 | 5.1 | 7 | NEUTRAL | -2.0 |
| BAYRY Bayer AG | $48B | -26.2 | -5.5 | 6.4 | 2.0 | -1.5 | 4 | LEAN BEAR | 59.6 |
| ARGX argenx SE | $55B | 41.0 | 26.0 | 50.1 | 29.8 | 162.5 | 7 | LEAN BEAR | 8.0 |
| WUXAY WuXi AppTec Co., Ltd. | $68B | 15.4 | 30.2 | 35.4 | 39.1 | 25.0 | 8 | BEARISH | 66.6 |
| TAK Takeda Pharmaceutical Company Limited | $63B | 56.1 | 2.5 | 2.9 | 9.3 | 4.0 | 6 | BULLISH | 44.8 |
| ABBV AbbVie Inc. | $505B | 80.7 | -206.4 | 23.5 | 21.3 | 10.4 | 7 | BULLISH | 25.6 |
| LZAGY Lonza Group AG | $54B | -412.9 | 13.5 | 10.5 | 17.5 | -9.7 | 8 | BULLISH | 4.3 |
| RPRX Royalty Pharma plc | $28B | 27.1 | 12.4 | 10.6 | 2.7 | 10.0 | 6 | BULLISH | 76.2 |
| WST West Pharmaceutical Services, Inc. | $28B | 50.5 | 19.1 | 19.0 | 17.7 | 12.4 | 9 | BULLISH | 34.0 |
| LH Labcorp Holdings Inc. | $27B | 27.0 | 11.7 | 8.6 | 8.0 | 6.4 | 8 | BULLISH | 19.8 |
| MEDP Medpace Holdings, Inc. | $19B | 36.7 | 117.9 | 1953.7 | 19.2 | 20.4 | 9 | BULLISH | 11.3 |
| CRL Charles River Laboratories International, Inc. | $17B | -73.8 | -7.7 | 6.9 | -0.1 | -0.7 | 4 | BULLISH | 82.2 |
| ASND Ascendis Pharma A/S | $15B | 18.2 | 121.1 | 76.2 | 61.0 | 114.8 | 7 | BULLISH | 21.7 |
| HALO Halozyme Therapeutics, Inc. | $14B | 36.5 | 173.7 | 32.5 | 47.8 | 41.2 | 5 | BULLISH | 94.3 |
| QGEN Qiagen N.V. | $10B | 25.8 | 11.9 | 11.2 | 19.3 | 3.0 | 8 | BULLISH | 1.7 |
| JNJ Johnson & Johnson | $636B | 40.7 | 20.0 | 21.3 | 0.8 | 7.8 | 6 | BULLISH | 42.0 |
| TMO Thermo Fisher Scientific Inc. | $249B | 36.9 | 13.4 | 8.6 | 14.2 | 8.3 | 8 | BULLISH | 21.2 |
| DHR Danaher Corporation | $162B | 37.9 | 8.3 | 6.3 | 18.8 | 5.5 | 7 | BULLISH | 4.8 |
| MDT Medtronic Plc | $122B | 23.0 | 10.7 | 7.8 | 15.1 | 9.8 | 9 | BULLISH | 3.6 |
| REGN Regeneron Pharmaceuticals, Inc. | $83B | 19.4 | 14.0 | 12.9 | 30.2 | 9.3 | 7 | BULLISH | 41.4 |
| CI Cigna Corporation | $81B | 12.3 | 15.5 | 11.8 | 2.3 | 7.7 | 8 | BULLISH | -0.6 |
| EW Edwards Lifesciences Corporation | $51B | 52.1 | 9.5 | 17.9 | 13.9 | 14.6 | 6 | BULLISH | 19.3 |
| SDZNY Sandoz Group AG | $42B | 66.5 | 7.2 | 10.1 | 1.9 | 29.1 | 6 | BULLISH | 59.1 |
| ILMN Illumina, Inc. | $41B | 51.6 | 32.4 | 18.2 | 17.9 | 4.9 | 7 | BULLISH | 179.2 |
| MTD Mettler-Toledo International Inc. | $33B | 37.8 | -736.4 | 46.7 | 22.7 | 6.9 | 8 | BULLISH | 17.5 |
| ORINY Orion Oyj | $30B | 23.0 | 53.6 | 46.3 | 26.9 | 22.6 | 7 | BULLISH | 44.0 |
| EXEL Exelixis, Inc. | $16B | 19.8 | 44.4 | 69.0 | 33.7 | 9.2 | 8 | BULLISH | 68.8 |
| PMCUF Pro Medicus Limited | $13B | 78.1 | 75.0 | 68.1 | 68.7 | 22.8 | 7 | BULLISH | -33.0 |
| AVTR Avantor, Inc. | $12B | -20.5 | -9.7 | -2.5 | 2.3 | -1.6 | 6 | BULLISH | 11.1 |
| GKOS Glaukos Corporation | $11B | -56.4 | -26.0 | -12.7 | -9.9 | 41.5 | 3 | BULLISH | 142.7 |
| GEHC GE HealthCare Technologies Inc. | $32B | 20.5 | 15.4 | 10.6 | 10.8 | 1.4 | 5 | BULLISH | -9.0 |
| ABT Abbott Laboratories | $179B | 38.2 | 10.7 | 7.3 | 7.4 | 8.1 | 5 | BULLISH | -18.7 |
| SNY Sanofi | $100B | 23.0 | 5.7 | 6.4 | 2.8 | 13.4 | 6 | BULLISH | -18.9 |
| UTHR United Therapeutics Corporation | $25B | 19.5 | 19.3 | 31.3 | 42.5 | 2.5 | 6 | BULLISH | 41.2 |
| GH Guardant Health, Inc. | $23B | -51.1 | 171.6 | -88.3 | -35.9 | 42.7 | 6 | BULLISH | 146.8 |
| RDY Dr. Reddy's Laboratories Limited | $11B | 39.0 | 7.5 | 6.0 | 10.7 | -3.1 | 4 | BULLISH | -5.7 |
| PODD Insulet Corp. | $10B | 27.9 | 26.0 | 21.3 | 11.8 | 29.4 | 9 | BULLISH | -53.3 |
| PFE Pfizer Inc. | $171B | 39.3 | 5.0 | 11.3 | -1.6 | -0.2 | 7 | BULLISH | 22.5 |
| MCK McKesson Corporation | $117B | 25.8 | -148.0 | 237.7 | 0.6 | 8.8 | 8 | BULLISH | 20.7 |
| WILYY Demant A/S | $12B | 46.8 | 15.9 | 10.9 | 9.1 | 10.6 | 5 | BULLISH | 47.3 |
| NTRA Natera, Inc. | $58B | -303.0 | -12.5 | -23.6 | -8.9 | 37.8 | 6 | BULLISH | 113.4 |
| IDXX IDEXX Laboratories, Inc. | $44B | 39.6 | 74.2 | 46.5 | 27.8 | 12.8 | 9 | BULLISH | -12.4 |
| ZTS Zoetis Inc. | $33B | 12.9 | 64.4 | 26.3 | 28.0 | 1.4 | 6 | BULLISH | -46.2 |
| CLPBY Coloplast A/S | $17B | 38.9 | 18.5 | 70.9 | 19.9 | -2.9 | 5 | BULLISH | -23.4 |
| SNN Smith & Nephew plc | $13B | 19.7 | 11.8 | 9.9 | 9.8 | 5.3 | 7 | BULLISH | -15.5 |
| PEN Penumbra, Inc. | $13B | 79.3 | 11.4 | 13.6 | 8.9 | 17.6 | 6 | BULLISH | 28.1 |
| COO The Cooper Companies, Inc. | $12B | 20.4 | 6.8 | 6.3 | 40.6 | 4.7 | 6 | BULLISH | -18.5 |
| RHHBF Roche Holding AG | $393B | 26.0 | 40.2 | 24.6 | 22.6 | 27.8 | 6 | BULLISH | 30.5 |
| NVS Novartis AG | $287B | 23.6 | 30.6 | 16.8 | 22.7 | 0.8 | 5 | BULLISH | 20.3 |
| GILD Gilead Sciences, Inc. | $193B | -60.9 | -20.6 | -3.4 | -134.5 | 5.5 | 5 | BULLISH | 32.4 |
| ISRG Intuitive Surgical, Inc. | $160B | 53.2 | 18.0 | 22.6 | 17.1 | 20.5 | 7 | BULLISH | -18.4 |
| CVS CVS Health Corp. | $120B | 23.8 | 6.2 | 4.9 | 2.8 | 7.4 | 8 | BULLISH | 11.2 |
| SYK Stryker Corporation | $118B | 31.0 | 16.5 | 11.6 | 19.4 | 8.5 | 9 | BULLISH | -21.0 |
| SOAGY Sartorius AG ADR | $92B | 92.0 | 7.7 | 6.6 | 7.1 | 4.3 | 7 | BULLISH | 16.0 |
| WAT Waters Corporation | $45B | 116.7 | 1.9 | 1.5 | -8.3 | 52.5 | 5 | BULLISH | 30.3 |
| BIIB Biogen Inc. | $37B | 44.4 | 4.6 | 4.8 | 3.6 | -0.5 | 3 | BULLISH | 68.6 |
| GNMSF Genmab A/S | $28B | 34.9 | 3.9 | 11.9 | 26.2 | -82.1 | 4 | BULLISH | 47.7 |
| VTRS Viatris Inc. | $21B | -52.2 | -2.8 | -0.3 | -3.2 | 4.4 | 7 | BULLISH | 83.0 |
| ALGN Align Technology, Inc. | $11B | 26.4 | 10.2 | 12.3 | 10.3 | 4.4 | 7 | BULLISH | 12.4 |
| CHGCF Chugai Pharmaceutical Co., Ltd. | $74B | 23.3 | 23.7 | 45.1 | 34.1 | 12.6 | 6 | BULLISH | -0.7 |
| NBIX Neurocrine Biosciences, Inc. | $15B | 20.6 | 22.1 | 16.0 | 15.1 | 34.4 | 6 | BULLISH | 1.4 |
| LLY Eli Lilly and Company | $1.2T | 42.8 | 102.4 | 39.2 | 30.9 | 49.6 | 9 | BULLISH | 55.5 |
| AMGN Amgen Inc. | $237B | 27.5 | 91.5 | 19.5 | 23.6 | 9.2 | 8 | BULLISH | 57.8 |
| CSLLY CSL Limited | $134B | -26.1 | -15.2 | 13.1 | -40.2 | 1.7 | 4 | BULLISH | 1.4 |
| CAH Cardinal Health, Inc. | $58B | 34.0 | -60.5 | 92.8 | 0.6 | 14.2 | 8 | BULLISH | 53.7 |
| BDX Becton, Dickinson and Company | $54B | 58.9 | 3.8 | 4.1 | 7.6 | -2.6 | 6 | BULLISH | 5.5 |
| A Agilent Technologies, Inc. | $49B | 35.1 | 21.0 | 14.9 | 19.3 | 8.6 | 7 | BULLISH | 19.9 |
| IQV IQVIA Holdings Inc. | $46B | 32.9 | 21.7 | 33.3 | 7.9 | 8.8 | 9 | BULLISH | 23.1 |
| OTSKY Otsuka Holdings Co., Ltd. | $42B | 16.0 | 13.8 | 12.2 | 16.7 | 10.9 | 8 | BULLISH | 44.2 |
| TRUMY Terumo Corporation | $22B | 21.5 | 11.0 | 9.6 | 22.6 | 15.6 | 5 | BULLISH | -8.6 |
| SONVF Sonova Holding AG | $20B | 38.9 | 20.4 | 17.2 | 19.7 | -7.1 | 6 | BULLISH | 22.9 |
| ZBH Zimmer Biomet Holdings, Inc. | $19B | 23.4 | 6.4 | 5.9 | 9.1 | 8.6 | 6 | BULLISH | -6.8 |
| ICLR ICON Public Limited Company | $14B | 42.8 | 3.5 | 5.5 | 3.5 | 2.0 | 6 | BULLISH | 2.7 |
| FSNUY Fresenius SE & Co. KGaA | $117B | 16.8 | 8.1 | 5.6 | 6.4 | 5.9 | 7 | BULLISH | -20.4 |
| GSK GSK plc | $102B | 16.0 | 25.5 | 18.8 | 5.2 | 5.0 | 7 | BULLISH | 18.9 |
| SEMHF Siemens Healthineers AG | $53B | 21.1 | 12.1 | 8.4 | 11.6 | 10.0 | 9 | BULLISH | -17.9 |
| DGX Quest Diagnostics Incorporated | $27B | 23.7 | 15.2 | 10.2 | 10.1 | 9.1 | 8 | BULLISH | 33.1 |
| SAUHY Straumann Holding AG | $19B | 41.9 | 17.3 | 21.7 | 18.1 | 3.0 | 6 | BULLISH | 4.9 |
| CNC Centene Corp. | $35B | 23.2 | 6.8 | 6.4 | -0.1 | 4.8 | 7 | BULLISH | 101.6 |
| RVTY Revvity, Inc. | $18B | 76.9 | 3.2 | 3.5 | 7.1 | 5.5 | 6 | BULLISH | 63.7 |
| BAX Baxter International Inc. | $13B | -12.2 | -15.7 | -1.6 | 4.3 | 5.4 | 3 | BULLISH | 8.4 |
| TECH Bio-Techne Corporation | $11B | 62.1 | 9.0 | 8.9 | 17.0 | -0.4 | 7 | BULLISH | 10.3 |
| MRNA Moderna, Inc. | $80B | -25.8 | -39.0 | -90.1 | -539.3 | -27.2 | 2 | BULLISH | 724.0 |
| HOCPY HOYA Corporation | $56B | 33.4 | 27.3 | 46.1 | 25.7 | 14.2 | 6 | BULLISH | 12.2 |
| HLN Haleon plc | $45B | 20.7 | 10.1 | 8.4 | 13.6 | 1.3 | 8 | BULLISH | 8.9 |
| ALC Alcon Inc. | $34B | 53.4 | 2.9 | 3.6 | 0.0 | 7.8 | 6 | BULLISH | -8.8 |
| PHG Koninklijke Philips N.V. | $26B | 20.3 | 10.2 | 7.6 | 8.8 | -1.1 | 6 | BULLISH | -8.4 |
| STE STERIS plc | $23B | 27.9 | 11.4 | 9.7 | 13.4 | 8.4 | 8 | BULLISH | -4.9 |
| SRTOY Sartorius Stedim Biotech S.A. | $228B | 66.4 | 7.4 | 6.2 | 12.5 | 4.4 | 8 | BULLISH | -0.5 |
| ESLOF EssilorLuxottica S.A. | $94B | 33.7 | 6.5 | 5.2 | 10.6 | 7.4 | 6 | BULLISH | -44.5 |
| BSX Boston Scientific Corporation | $66B | 18.1 | 15.5 | 11.6 | 16.7 | 13.5 | 8 | BULLISH | -55.4 |
| ROIV Roivant Sciences Ltd. | $26B | -95.9 | -6.2 | -217.5 | -13164.4 | -67.6 | 1 | BULLISH | 100.5 |
| BMXXY bioMérieux S.A. | $12B | 22.8 | 11.2 | 8.9 | 11.5 | -3.5 | 7 | BULLISH | -28.0 |
| GMED Globus Medical, Inc. | $11B | 20.4 | 11.8 | 12.3 | 19.2 | 19.7 | 8 | BULLISH | 29.8 |
| ELV Elevance Health Inc. | $95B | 17.9 | 11.6 | 16.2 | 2.7 | 3.6 | 7 | BULLISH | 23.7 |
| TEVA Teva Pharmaceutical Industries Limited | $46B | 64.2 | 9.7 | 9.3 | -13.9 | 4.1 | 7 | BULLISH | 113.2 |
| BBIO BridgeBio Pharma, Inc. | $13B | -19.3 | 32.4 | 57.9 | -62.5 | 202.4 | 4 | BULLISH | 27.9 |
| ONC BeOne Medicines AG | $40B | 25.2 | 14.7 | 57.2 | 13.9 | 34.3 | 8 | BULLISH | 17.9 |
| UNH UnitedHealth Group Incorporated | $375B | 23.4 | 15.9 | 13.5 | 3.6 | 3.3 | 7 | BULLISH | 14.0 |
| FSPKF Fisher & Paykel Healthcare Corporation Limited | $16B | 60.2 | 23.3 | 27.3 | 20.6 | 5.0 | 6 | BULLISH | 34.9 |
| RCDTF Recordati Industria Chimica e Farmaceutica S.p.A. | $12B | 21.7 | 24.9 | 15.4 | 16.7 | 9.2 | 7 | BULLISH | -9.2 |
| VRTX Vertex Pharmaceuticals Incorporated | $133B | 29.9 | 23.5 | 28.3 | 33.0 | 10.6 | 6 | BULLISH | 23.6 |
| SGIOY Shionogi & Co., Ltd. | $16B | 9.8 | 13.6 | 9.9 | 50.6 | 10.3 | 5 | BULLISH | 20.6 |
| ERFSF Eurofins Scientific SE | $17B | 28.5 | 12.8 | 4.6 | 8.2 | 3.3 | 6 | BULLISH | 25.6 |
| HUM Humana Inc. | $51B | 38.9 | 6.8 | 17.2 | 1.7 | 18.3 | 4 | BULLISH | 42.7 |
| UCBJY UCB S.A. | $58B | 23.3 | 20.7 | 16.4 | 26.0 | 25.3 | 6 | LEAN BULL | 5.8 |
| BIOVF Swedish Orphan Biovitrum AB | $16B | 116.9 | 3.4 | 17.2 | 14.0 | 13.3 | 4 | LEAN BULL | 37.3 |
| AZN AstraZeneca PLC | $266B | 25.4 | 22.0 | 15.0 | 16.3 | 8.6 | 9 | LEAN BULL | 4.5 |
| IPSEY Ipsen S.A. | $58B | 24.6 | 11.5 | 16.3 | 18.2 | 8.0 | 6 | LEAN BULL | 22.7 |
| BMY Bristol-Myers Squibb Company | $126B | 13.5 | 46.7 | 17.8 | 25.6 | 3.1 | 8 | LEAN BULL | 46.8 |
| MKGAF Merck KGaA | $70B | 26.5 | 8.1 | 8.1 | 9.0 | -0.4 | 7 | LEAN BULL | 19.4 |
| ALPMF Astellas Pharma Inc. | $30B | 12.4 | 21.4 | 16.9 | 22.1 | 17.3 | 7 | LEAN BULL | 60.4 |
| JDHIY JD Health International Inc. | $16B | 16.4 | 10.3 | 31.0 | 8.4 | 19.6 | 6 | LEAN BULL | -43.9 |
| TEM Tempus AI, Inc. | $12B | -50.6 | -67.4 | -19.8 | 1.5 | 50.4 | 4 | LEAN BULL | -19.1 |
| FMS Fresenius Medical Care AG & Co. KGaA | $12B | 12.2 | 7.3 | 6.7 | 4.5 | -0.5 | 7 | NEUTRAL | -17.4 |
| COR Cencora, Inc. | $63B | 24.2 | 104.3 | 26.5 | 0.9 | 5.1 | 7 | NEUTRAL | -2.0 |
| HCA HCA Healthcare, Inc. | $102B | 53.8 | -124.7 | 23.3 | 8.4 | 7.3 | 6 | NEUTRAL | 0.8 |
| AAVXF Abivax S.A. | $12B | -17.0 | -221.8 | 440.6 | — | -133.5 | 4 | NEUTRAL | 57.0 |
| CHJTF CSPC Pharmaceutical Group Limited | $14B | 10.3 | 20.7 | 36.7 | 32.8 | 88.1 | 6 | NEUTRAL | 13.3 |
| DVA DaVita Inc. | $12B | 15.6 | -149.4 | 17.9 | 7.5 | 6.4 | 8 | NEUTRAL | 40.7 |
| NONOF Novo Nordisk A/S | $172B | 9.9 | 59.8 | 35.2 | 26.7 | 5.6 | 5 | NEUTRAL | -28.1 |
| IHHHF IHH Healthcare Berhad | $15B | 30.9 | 7.3 | 6.1 | 8.1 | 7.1 | 5 | NEUTRAL | 43.7 |
| BAYRY Bayer AG | $48B | -26.2 | -5.5 | 6.4 | 2.0 | -1.5 | 4 | LEAN BEAR | 59.6 |
| SUVPF Sartorius AG | $19B | 92.0 | 7.7 | 6.7 | 7.1 | 3.6 | 7 | LEAN BEAR | -0.5 |
| ARGX argenx SE | $55B | 41.0 | 26.0 | 50.1 | 29.8 | 162.5 | 7 | LEAN BEAR | 8.0 |
| MOH Molina Healthcare, Inc. | $11B | -323.5 | -1.2 | -44.2 | 0.4 | -2.1 | 5 | LEAN BEAR | 22.1 |
| INCY Incyte Corporation | $23B | 14.3 | 30.7 | 82.1 | 35.0 | 26.9 | 8 | LEAN BEAR | 27.7 |
| DSNKY Daiichi Sankyo Company, Limited | $33B | 19.6 | 15.1 | 12.5 | 11.9 | 17.4 | 5 | LEAN BEAR | -37.5 |
| BTSG BrightSpring Health Services, Inc. Common Stock | $12B | 40.8 | 15.5 | 10.3 | 2.2 | 19.9 | 7 | LEAN BEAR | 74.0 |
| WXIBF WuXi Biologics (Cayman) Inc. | $26B | 31.4 | 10.6 | 16.0 | 20.7 | 16.0 | 9 | BEARISH | 20.2 |
| EHC Encompass Health Corporation | $12B | 19.5 | 25.5 | 16.7 | 9.6 | 9.5 | 9 | BEARISH | -3.7 |
| RSMDF ResMed Inc. | $36B | 24.1 | 24.3 | 25.3 | 26.2 | 9.9 | 7 | BEARISH | -15.5 |
| BTSGU BrightSpring Health Services, Inc. Tangible Equity Unit | $12B | 40.8 | 15.5 | 10.3 | 2.2 | 19.9 | 7 | BEARISH | 68.8 |
| UHS Universal Health Services, Inc. | $11B | 7.1 | 21.0 | 12.5 | 7.7 | 10.0 | 8 | BEARISH | -15.7 |
| RGEN Repligen Corporation | $11B | -831.3 | -0.6 | -1.4 | -18.4 | 13.8 | 4 | BEARISH | 5.7 |
| SOLV Solventum Corporation | $15B | 10.1 | 34.0 | 18.1 | 4.2 | -0.9 | 7 | BEARISH | 16.2 |
| THC Tenet Healthcare Corporation | $22B | 10.0 | 53.3 | 19.1 | 14.7 | 5.4 | 7 | BEARISH | 24.5 |
| OCPNF Olympus Corporation | $12B | 24.6 | 10.6 | 12.7 | 7.9 | 7.8 | 5 | BEARISH | -9.8 |
| IVBXF Innovent Biologics, Inc. | $20B | 96.9 | 6.9 | 67.2 | 14.5 | 35.4 | 6 | BEARISH | -11.4 |
| ELAN Elanco Animal Health Incorporated | $11B | -55.3 | -3.0 | 3.7 | 3.9 | 12.0 | 5 | BEARISH | 2.7 |
| RVMDW Revolution Medicines, Inc. Warrant | $40B | -21.0 | -79.1 | 186.4 | — | — | 1 | BEARISH | 2251.5 |
| ALNY Alnylam Pharmaceuticals, Inc. | $30B | 37.2 | 100.7 | -152.8 | 12.7 | 95.1 | 6 | BEARISH | -51.1 |
| ENSG The Ensign Group, Inc. | $10B | 25.8 | 17.0 | 8.1 | 6.9 | 18.9 | 7 | BEARISH | -8.9 |
| MRK Merck & Co., Inc. | $358B | 112.5 | 7.0 | 6.1 | -8.0 | 4.5 | 4 | BEARISH | 63.5 |
| BMRN BioMarin Pharmaceutical Inc. | $11B | 146.2 | 1.2 | 1.4 | 4.5 | 11.2 | 4 | BEARISH | 1.6 |
| WUXAY WuXi AppTec Co., Ltd. | $68B | 15.4 | 30.2 | 35.4 | 39.1 | 25.0 | 8 | BEARISH | 66.6 |
| DXCM DexCom, Inc. | $29B | 30.5 | 38.5 | 42.9 | 19.0 | 15.5 | 9 | BEARISH | 11.7 |
| RVMD Revolution Medicines, Inc. | $40B | -21.0 | -79.1 | 186.4 | — | — | 1 | BEARISH | 241.8 |
| BNTX BioNTech SE | $22B | -11.5 | -9.3 | -18.0 | -777.3 | -8.2 | 2 | BEARISH | -17.6 |
| JAZZ Jazz Pharmaceuticals plc | $14B | 13.6 | 22.1 | 26.4 | 16.0 | 12.6 | 8 | BEARISH | 49.3 |
| MDGL Madrigal Pharmaceuticals, Inc. | $10B | -34.1 | -53.3 | -778.9 | -15.9 | 149.0 | 2 | BEARISH | 4.5 |
| INSM Insmed Incorporated | $20B | -23.0 | -87.2 | -364.8 | -3.1 | 185.8 | 5 | BEARISH | -40.5 |
| GIKLY Grifols, S.A. | $15B | 15.9 | 8.4 | 7.4 | 8.2 | -0.2 | 6 | BEARISH | -19.0 |
| MDLN Medline Inc. | $30B | 37.9 | 3.2 | 4.4 | 0.8 | — | 4 | BEARISH | — |
| SMMT Summit Therapeutics Inc. | $12B | -13.7 | -192.5 | 1714.4 | — | — | 3 | BEARISH | -20.5 |
| SBMFF Sino Biopharmaceutical Limited | $12B | 30.4 | 21.1 | 40.0 | 17.7 | 28.2 | 7 | BEARISH | -22.9 |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
TAK vs Benchmarks
ROIC
Gross Margin
Op Margin
Net Margin
Revenue Growth
P/E Ratio
ROE
Piotroski F